SCHEMBL6307136

SCHEMBL6307136

CCOC(=O)c1cc2cc(N3CCOCC3)ccc2[nH]1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.60
ALDH1A1 P00352 3/20 0.60
HPGD P15428 3/20 0.60
RAB9A P51151 3/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
HSD17B10 Q99714 1/20 0.60
NPC1 O15118 2/20 0.56
LMNA P02545 2/20 0.56
HTT P42858 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
HRH3 Q9Y5N1 1/20 0.56
SIRT2 Q8IXJ6 1/20 0.55
SIRT1 Q96EB6 1/20 0.55
MMP13 P45452 6/20 0.55
MMP2 P08253 5/20 0.55
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
GLA P06280 1/20 0.52
GAA P10253 1/20 0.52
MAPT P10636 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27518073 0.89 KDM4E (0.64) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL15642611 0.84 KDM4E (0.57) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL16792606 0.82 HRH3 (0.63) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL7076175 0.81 SMAD3 (0.51) KDM4EALDH1A1HPGDSMN1; SMN2HSD17B10
SCHEMBL18332155 0.81 KDM4E (0.51) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL30492811 0.80 ALOX15 (0.58) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL18332381 0.80 KDM4E (0.50) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL18332158 0.79 ALDH1A1 (0.50) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL5843451 0.78 ALDH1A1 (0.58) KDM4EALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL3432670 0.78 PDGFRB (0.70) KDM4EALDH1A1HPGDRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6953809-B2 Monocyte chemoattractant protein-1 inhibitor compounds ZENECA LIMITED (GB) 2005-10-11 US disclosed
US-20030119830-A1 Monocyte chemoattractant protein-1 inhibitor compounds ZENECA LIMITED 2003-06-26 US disclosed
US-6441004-B1 INDOLE DERIVATIVES AS ANTIINFLAMMATORY AGENTS ZENECA LIMITED (GB) 2002-08-27 US disclosed
CN-1265591-A Coumpound ZENECA LTD (GB) 2000-09-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119830-A1 Monocyte chemoattractant protein-1 inhibitor compounds CCL2, CCL11, CCR1 KDM4E 3717/4885ALDH1A1 1888/4885HPGD 1094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.